115 related articles for article (PubMed ID: 9762343)
21. New ribonucleotide reductase inhibitors with antineoplastic activity.
Elford HL; Wampler GL; van't Riet B
Cancer Res; 1979 Mar; 39(3):844-51. PubMed ID: 427774
[No Abstract] [Full Text] [Related]
22. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy.
Witt L; Yap T; Blakley RL
Adv Enzyme Regul; 1978; 17():157-71. PubMed ID: 316642
[No Abstract] [Full Text] [Related]
23. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
Weckbecker G; Weckbecker A; Lien EJ; Cory JG
J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
[TBL] [Abstract][Full Text] [Related]
24. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
26. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
Carter GL; Cory JG
Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of protein disulfide isomerase-like protein in a mouse leukemia L1210 cell line selected for resistance to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a ribonucleotide reductase inhibitor.
Crenshaw TR; Cory JG
Adv Enzyme Regul; 2002; 42():143-57. PubMed ID: 12123712
[No Abstract] [Full Text] [Related]
28. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
Gao WY; Zhou BS; Johns DG; Mitsuya H; Yen Y
Biochem Pharmacol; 1998 Jul; 56(1):105-12. PubMed ID: 9698094
[TBL] [Abstract][Full Text] [Related]
29. Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.
Nocentini G; Barzi A; Franchetti P
Cancer Chemother Pharmacol; 1990; 26(5):345-51. PubMed ID: 2208576
[TBL] [Abstract][Full Text] [Related]
30. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
Cory AH; Samano V; Robins MJ; Cory JG
Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
[TBL] [Abstract][Full Text] [Related]
31. Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.
Nocentini G; Barzi A
Pharmacol Res; 1990; 22 Suppl 1():39-40. PubMed ID: 2284243
[No Abstract] [Full Text] [Related]
32. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Crenshaw TR; Cory JG
Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
[TBL] [Abstract][Full Text] [Related]
33. Quenching of tyrosine radicals of M2 subunit from ribonucleotide reductase in tumor cells by different antitumor agents: an EPR study.
Liermann B; Lassmann G; Langen P
Free Radic Biol Med; 1990; 9(1):1-4. PubMed ID: 2170241
[TBL] [Abstract][Full Text] [Related]
34. Increased ribonucleotide reductase activity in hydroxyurea-resistant mosquito cells.
Gerenday A; Shih KM; Herman CC; Fallon AM
Arch Insect Biochem Physiol; 2001; 46(1-2):19-25. PubMed ID: 11276057
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of ribonucleotide reductase by caracemide.
Moore EC; Loo TL
Cancer Treat Rep; 1984 Oct; 68(10):1293-4. PubMed ID: 6395952
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells.
Leyden D; Ahmed N; Hassan HT
Anticancer Res; 2000; 20(1A):133-8. PubMed ID: 10769645
[TBL] [Abstract][Full Text] [Related]
37. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
Giacca M; Borella S; Calderazzo F; Bianchi LC; D'Agaro P; Rampazzo C; Bianchi V; Reichard P
AIDS Res Hum Retroviruses; 1996 May; 12(8):677-82. PubMed ID: 8744578
[TBL] [Abstract][Full Text] [Related]
38. Ribonucleotide reductase as a chemotherapeutic target.
Cory JG
Adv Enzyme Regul; 1988; 27():437-55. PubMed ID: 3074632
[TBL] [Abstract][Full Text] [Related]
39. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity.
Easmon J; Heinisch G; Pürstinger G; Langer T; Osterreicher JK; Grunicke HH; Hofmann J
J Med Chem; 1997 Dec; 40(26):4420-5. PubMed ID: 9435912
[TBL] [Abstract][Full Text] [Related]
40. [The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases].
Findenig G; Vielnascher E; Göbl R; Fritzer-Szekeres M; Szekeres T
Wien Klin Wochenschr; 1995; 107(22):694-7. PubMed ID: 8533431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
